Destruction of the insulin-secreting B cells of the pancreas is responsible for Type 1 (insulin-dependent) diabetes mellitus. A variety of factors including viruses, chemicals and immune reactions mediated by cells or antibodies have been implicated as possible causes of this destruction [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Over the last few years it has become clear that autoimmune abnormalities are associated with the majority of cases of Type 1 diabetes mellitus. Whether these autoimmune abnormalities are the exclusive cause, a contributing factor, the result, or simply a marker for pancreatic B-cell damage is still not absolutely clear. What triggers the autoimmune response al, so is not known.
In this review, we summarize the evidence showing that Type 1 diabetes mellitus is characterized by not only an autoimmune response to pancreatic B cells, but also by a variety of other immunological abnormalities; that some of these abnormalities are transient; and that perturbations in the regulation of insulin secretion may affect immune responsiveness. Where possible, we have presented the data in a quantitative or semiquantitative form so that the state of knowledge could be better evaluated. For purposes of comparison, some of the data from original articles were put in a different format and recalculated.
Multiple autoantibodies
The most commonly reported immunological abnormality in Type I diabetes mellitus is autoantibodies reacting with pancreatic islet-cell antigens [reviewed in 2, 6, [11] [12] [13] . These antibodies have been divided into two types, one reacting with cytoplasmic antigens (ICA) and the other reacting with surface antigens (ICSA). In general, ICA are detected by indirect immunofluorescence on frozen sections of human pancreas, whereas ICSA are detected on viable cells using direct cytotoxicity [14, 15] , immunofluorescence [16] or radioimmu-* Current address: Laboratory of Virus and Cancer Research, Department of Medicine, George Washington University Medical Center, Washington, D.C., USA noassay [171. In patients with recently diagnosed Type 1 diabetes ICA are found in over 60% of cases [11] [12] [13] [18] [19] [20] , while in non-diabetic control subjects ICA are found in 0.5-2% [19] [20] [21] [22] [23] [24] of cases. Recent reports indicate that ICA can be detected in some individuals months or even years prior to the onset of clinical symptoms of diabetes, suggesting that Type 1 diabetes may have a longer and more chronic course than previously thought, and that ICA may be a marker for detecting Type 1 diabetes [25] [26] [27] [28] .
What is perhaps not as fully appreciated is that, in addition to islet cell antibodies, a variety of other autoantibodies are elevated in patients with Type I diabetes mellitus. Moreover, the frequency of other autoimmune diseases is higher in diabetic patients than in the normal population [29] [30] [31] . Some of the autoantibodies found in Type 1 diabetes are listed in Table I [14, 19, [20] [21] [22] [23] [24] , along with reported frequencies in both Type 1 diabetic patients and control subjects. For some of the autoantibodies the data base is not large, whereas for others it is quite extensive. In some cases data were pooled from several studies to calculate an overall percentage. In addition to autoantibodies to islet cells, autoantibodies to insulin and insulin receptors are found in Type I diabetic patients but rarely in non-diabetic subjects. Similarly, autoantibodies to a variety of nonpancreatic antigens are found in patients with Type 1 diabetes. For example, more Type I patients as compared to control subjects have autoantibodies to B lymphocytes (19.1% vs. 4.3%), gastric parietal cells (11.1% vs. 5.8%), thyroid microsomal antigens (17.9% vs. 5.8%), thyroglobulin (10% vs. 4.4%), anterior pituitary (19.7% vs.0%) and nuclear antigens (9.9% vs. 1.6%) [21, 45-56, 58, 60, 61, 64, 65] . Three studies on autoantibodies to adrenal gland antigens have appeared, one [43] to adrenal medulla and two [52, 56] to adrenal cortex. All report a higher frequency in Type I diabetic patients than in control subjects both for autoantibodies to adrenal medulla (39.5% vs. 0.7%) and autoantibodies to adrenal cortex (1.9% vs. 0.5%). Wide divergences in frequencies have been reported for autoantibodies to isletcell surface antigens (36% to 65%), insulin (20% to 69%) and pancreatic A cells (1% to 37%) [ 44] . Despite the great variability and small sample size in certain studies, it is clear from the data summarized in Table I that patients with Type i diabetes mellitus have autoantibodies that are directed against a wide variety of non-pancreatic antigens in addition to those directed against islet cells.
Duration of autoantibodies
The frequency of ICA in the serum of Type I diabetic patients declines following diagnosis [18, 20, 24, [72] [73] [74] [75] [76] .
From an initial frequency as high as 65% at diagnosis, the percentage of patients that have ICA declines to less than 20% after 2years. This raises the question of whether other autoantibodies also decline with time. Unfortunately, only a limited amount of data are available to address this question [18, 20, 21, 24, 32, 45, 47, 60, 62, 63, 70, 72] . q-hose autoantibodies for which data exist show a decline following diagnosis of diabetes similar to the decline in ICA ( [47] . It should be noted, however, that the frequency of autoantibodies to thyroid antigens appears to increase with age in the general population [53] . Further examination of the literature shows that autoantibodies to anterior pituitary cells, present in 16.6% of patients within 2 years of diagnosis of Type 1 diabetes, decline to 2.2% after 2years [60] . Similar declines are reported for autoantibodies in Type I diabetic patients to gastric parietal cells [47] and tubulin [62] , as well as for circulating immune complexes [70] [71] [72] . Table 3 summarizes some of the increasing number of reports describing abnormalities of cell-mediated immunity (CMI) in Type I diabetes mellitus. It is clear from the table that the scope of activities described as cell-mediated is quite broad, and the reports are not always consistent. Several groups have reported decreases (ranging from 2% to 18%) in total number of T cells in the circulation of Type 1 diabetic patients [79] [80] [81] [82] , and a reduction in circulating helper T cells is thought to be responsible [80] [81] [82] . The ratio of circulating helper T cells to circulating cytotoxic/suppressor T cells is described as altered by a number of groups, but it remains controversial whether in Type I diabetic patients this ratio is decreased [80, 81, 87] or increased [82, 84, 86] . Consistently, however, the percentage of activated T cells in the circulation, measured either as Interleukin-2 receptor-positive T cells [85] or as HLA DRantigen-positive T cells [81, 86, 87, 89] , is elevated in Type 1 diabetic patients. One report describes a decrease in Interleuldn-2 production by T cells from Type 1 diabetic patients [90] .
Multiple abnormalities of cell-mediated immunity
Other activities that have been reported to be abnormal in Type 1 diabetes mellitus include lymphocyte recognition of pancreatic antigens [91] [92] [93] [94] , phagocytic activity [100, 101] , blastogenesis in response to insulin [97] [98] [99] , as well as suppressor cell activities [93, 108, [110] [111] [112] [113] . Additional reports describe increased K-cell reactivity [102] , increased anti-islet-cell cytotoxicity [103, 104] and islet-specific suppressor cell activity [110] . Variable changes have been found in the mixed lymphocyte reaction (MLR) [95, 98] and mitogen responsiveness [96, 99, [105] [106] [107] [108] [109] . It is unclear, however, how much overlap there is in the immunological functions measured by the different assay systems. Moreover, different patient populations with varying degrees of metabolic control were used in these studies; this, in part, may account for the variation in results [100, 105, 109] . Selam et al. [105] , for example, found that the percentage of total T cells in the circulation in 39 diabetic patients correlated with the degree of metabolic control. In 14 well-controlled diabetic patients, the percentage of total T cells in the circulation was 70.8%, not different from the 71% in 50 non-diabetic control subjects. In contrast, in 25 poorly-controlled diabetic patients the percentage of Tcells in the circulation was 64.1%, significantly lower than the control subjects.
Perhaps the greatest source of uncertainty in interpreting these reports of abnormalities in cell-mediated immunity is that so few of them are islet cell specific. As more islet cell specific assays are developed, the extent of these abnormalities should become dearer.
Duration of cell-mediated immunological abnormalities
The data summarized in Table 4 show that some of the abnormalities in CMI return toward normal within 6 months to 2 years after diagnosis of Type I diabetes mellitus [ [93] , using the leukocyte migration test (which measures antigen-stimulated lymphokine release), found that 19 diabetic patients with disease for less than 2 years gave an average response to human pancreas antigen of 0.81 ___ 0.05, while 10 diabetic patients studied more than 2 years after diagnosis responded with an average migration index of 0.95 ___0.23 (1.0 being normal). Buschard et al. [113] found that non-specific Concanavalin-A-induced suppressor activity returned toward normal values with a low of 0.34 + 0.16 at or near diagnosis to 0.83 + 0.16 in the 6-month to 2-year interval, and up to 0.93 ___ 0.15 beyond 2 years (1.0 being normal). In other experiments, Pozzilli et al. [102] reported that 57% of newly diagnosed diabetic patients had elevated K-cell activity, and that this decreased to 16% between 6 months and 2 years after diagnosis. In studies of Interleukin-2 receptor expression on circulating T cells, Hayward and Herberger [85] reported that in 15 recently diagnosed diabetic patients, 6.2% of the lymphocytes had Interleukin-2 receptors, whereas in six diabetic patients with disease for longer than 2 years, only 2.3% of the lymphocytes had Interleukin-2 receptors (2% of control lymphocytes were Interieukin-2 receptor-positive). Two reports [82, 84] studying OKT4/OKT8 ratios in diabetic patients showed elevated values at or near diagnosis and decreased values after i or more years of disease.
Immunological abnormalities associated with experimental induction of diabetes
The possibility that some of the immunological abnormalities found in Type 1 diabetes mellitus might be secondary to pancreatic B-cell destruction and insulin deficiency was explored by reviewing the literature on chemicals (i. e. alloxan and streptozotocin) that induce diabetes in experimental animals by destroying B cells [114] [115] [116] . Other animal models of diabetes involving more complicated etiologies have been reviewed elsewhere [1, 116, 117] . The data summarized in Table 5 [118 -127] show that in animals with alloxan-induced diabetes, a number of immunological functions are depressed, including cellularity of the lymphoid organs [118, 119] , contact sensitivity to haptens [120, 121] , granuloma formation [122] , delayed-type hypersensitivity (DTH) reactions [122, 124] , humoral antibody responses [119, 123, 124] and the response to mitogens [124, 127] . In addition, the rejection time of skin grafts was prolonged [119] . Similarly, single-dose streptozotocin-treated mice showed many immunological abnormalities [122, 124, [128] [129] [130] [131] [132] [133] [134] [135] . As in alloxan-treated mice, lymphoid organ cellularity [128] [129] [130] [131] [132] , hapten sensitivity [130, 133] , delayed-type hypersensitivity [122, 124, 131] , humoral antibody responses [124, 131, 133, 134] , mitogen responses [124, 132] and phagocytic activity [133, 135] were all reduced. Reductions in the mixed lymphocyte reaction [129] , the generation of cytotoxic lymphocytes [129, 134] , tumour rejection [129] and allograft rejections [122] were also observed. Thus, many of the immunological abnormalities in chemically-induced diabetes parallel the abnormalities seen in human Type1 diabetes (Tables 1, 3) .
Restoration of immune function in vivo by insulin
Although it is tempting to attribute these immunological abnormalities to pancreatic B-cell destruction and a deficiency of insulin, streptozotocin and alloxan might have a direct injurious effect on the cells of the immune [132] ; d complete restoration reported via islet cell transplantation [134] ; e pokeweed mitogen; f at 9 days only; thereafter MLR was normal; g tested in mice 31 days after streptozotocin administration; subcutaneous tumour growth was evaluated 35 days post-implantation with tumour fragments system. In vitro experiments [124] have shown that streptozotocin decreased the viability of spleen and thymus cells, anti-SRBC plaque formation, PHA-, Concanavalin-A and LPS-responses, and Interleukin-1 and Interleukin-2 production. In contrast, up to 10 times the in vivo diabetogenic dose (1.1 mmol/1) of alloxan had little or no effect on in vitro immune function [124] . Nonetheless, the evidence that pancreatic B-cell destruction and the decrease in circulating insulin in alloxan-treated animals is responsible for the alterations in immune function must be interpreted with caution. Probably the best evidence that insulin deficiency can alter immune function comes from restoration experiments. As seen in Table 5 , insulin therapy can partially or completely restore a number of the immunological abnormalities [119, 120, 122, 124, 127, 129, 130, 134, 135] . More consistent reversals of immune deficits were achieved in alloxan-induced diabetes than in streptozotocin-induced diabetes. In alloxan-induced diabetic mice, complete or near complete restoration of lym- phoid organ cellularity, granuloma formation [122] , antibody responses [119, 123, 124] , graft rejection [119] , Concanavalin-A responsiveness [124] and DTH reactions [124] have been reported. In streptozotocin-induced diabetic animals.~ partial restorations of lymphoid organ cellularity [129, 130] , antibody responses [124, 134] , Concanavalin-A responsiveness and DTH responses [124] were achieved.
Effects of insulin on in vitro immune function
Further evidence that insulin can affect the function of the immune system comes from a variety of in vitro experiments (Table6) [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] . Rhodes [136] reported that insulin inhibited the expression of Fc receptors on guinea pig macrophages as measured by an erythrocyteantibody rosetting assay, but the concentration of insulin employed was in the 5 x 10 -5 mol/1 range; this is three to seven orders of magnitude larger than the concentration commonly regarded as physiological [137] [138] [139] . Similarly, Hunt and Eardley [148] reported inhibition of antibody formation and Interleukin-2-induced proliferation by these concentrations of insulin. When Lima etal. [137] used insulin in physiological doses (10 -9 to 10 -a3 mol/1), they found enhancement of phagocytic responses by murine peritoneal macrophages, a result confirmed by Kragballe et al. [138] using human monocytes. Using a different assay Bar et al. [139] reported inhibition of antibody-dependent cellular cytotoxicity by insulin (10 -1~ mol/1), but the inhibition was not dramatic (about 30%). Most investigators believe that resting lymphocytes are unresponsive to insulin because they do not express insulin receptors [140, 142, 144, 149] . Thus, for insulin to affect lymphocyte function, the lymphocytes must first become activated. Activation can occur following antigenic challenge, mitogen stimulation or co-culture with allogeneic cells [143, 149, 150] . In general, insulin enhances the responsiveness of already activated lymphocytes. Several investigators [140, 142, 143] have reported that insulin can increase the stimulation of murine lymphocytes by the mitogens PHA, Concanavalin-A and LPS. Others [138, 151] have noted similar in vitro effects of insulin on the metabolic activity of human leukocytes. Numerous reports on insulin-enhanced functions on activated cells have appeared as well. In vitro and in vivo, insulin increases murine plaque formation to sheep erythrocytes [143, 152] , the mixed leukocyte reaction in both murine and human cultures [144, 145] , and the development of cytotoxic effector cells lytic for 51Cr-labeled alloantigenic target cells [146, 147] . In vivo, it has been reported that the administration of insulin causes transient changes in human peripheral T-cell subsets [153] . Taken together, these studies show that, directly or indirectly, insulin can alter immune function.
Comme~
A review of the literature makes several points clear. First, although much attention has been given to ICA, autoantibodies to a variety of other tissues are present in patients with Type 1 diabetes meUitus. Moreover, patients with Type 1 diabetes show a number of cell-mediated immunological abnormalities. If Type i diabetes is triggered by a specific attack on pancreatic B cells, why are autoantibodies present that react with other tissues of the body? Although some antibodies to pancreatic B cells may cross-react with the other tissues, it seems unlikely that this is the sole explanation for the multiple organ-reactivity serum from patients with Type I diabe-tes [154] . A number of different antigen-specific antibody molecules are almost certainly present. If this is the case, one must then ask whether the antibodies to pancreatic B cells appear as part of a broader immunological dysfunction associated with Type 1 diabetes or whether these antibodies develop as a consequence of the disease process. The answer to this question is of central importance to understanding the etiology of Type 1 diabetes, and may help determine whether the primary defect resides in pancreatic B cells or in cells of the immune system.
The second point that a review of the literature makes clear is that certain of the immunological abnormalities are transient. For example, the frequency of ICA in Type 1 diabetes decreases from over 60% at the time of the initial diagnosis to less than 20% at 2 years after diagnosis. It is generally thought that this decrease in ICA reflects a loss of antigenic stimulation due to the depletion of the remaining pancreatic B cells. However, the data in Tables 2 and 4 make it clear that antibodies to tissues other than pancreatic B cells also decrease after diagnosis, and that a number of the cell-mediated immunological abnormalities return towards normal. In contrast to Type I diabetes, in other autoimmune diseases the autoantibodies may persist for years [155, 156] .
One fundamental difference between the pre-and post-diagnosis phase of Type 1 diabetes mellitus is that after diagnosis the patients are treated with maintenance doses of insulin. This raises the question as to whether insulin can influence immunlogical function. A review of the literature (Tables 5, 6) shows that insulin can have a profound effect on at least some immunological functions. Less clear is whether insulin deficiency induces the type of immunological abnormalities seen in Type I diabetes. If insulin deficiency does play a r61e, there are several possible modes of action. The first is that the destruction of pancreatic B cells is the result of an immunologically specific attack on B cells, triggered by still unknown factors, and that the generation of autoantibodies against non-pancreatic tissues is a consequence of the resulting insulin deficiency on the normal function of the immune system. The second is that an environmental insult (e.g. viruses or toxins) damages pancreatic B cells [4, 157] , and that the rise of autoantibodies to both pancreatic islets and non-pancreatic tissues is in part due to the resulting insulin deficiency and the effect it has on the normal function of the immune system. In either case, the administration of insulin after diagnosis, and the at least partial correction of host metabolism, might be responsible for the observed restoration of immunological function (Table 2) . Some support for this argument also comes from experiments in diabetic animals which have shown that administration of insulin can correct some of the immunological abnormalities (Table 5) . A third possibility is that glycosylation of proteins [158, 159] , which is known to be increased in Type I diabetes, makes self antigens foreign and induces autoantibodies. The administration of insulin would result in a decline of glycosylated proteins and a corresponding decrease in autoantibodies. A number of questions, however, remain to be answered and additional and more rigorous information is needed to determine if a deficiency or abnormality in insulin secretion truly plays a rrle. For example, does diabetes caused by partial pancreatectomy (to avoid the use of drugs that might affect lymphocyte function) in experimental animals induce immunological abnormalities? In humans, do subsets of lymphocytes from DR3 and DR4 individuals (who are known to be at higher risk of developing Type I diabetes) [160, 161] show more immunological abnormalities than lymphocytes from individuals with other HLAtypes if subjected to hypoinsulinaemia and hyperglycaemia? In high-risk first degree relatives of Type I diabetic patients, does the time of appearance of autoantibodies to non-pancreatic tissues correlate with the time of appearance of autoantibodies to pancreatic islets?
The work summarized here raises the possibility that immunological abnormalities may not only be a cause, but one of the complications of Type i diabetes mellitus. More information on this and related issues may provide useful clues to therapy. Aggressive insulin therapy has been used by some investigators to prolong the remission ("honeymoon") period [162] [163] [164] . It has been suggested that insulin acts by preventing exhaustion of the remaining pancreatic B cells. Another possibility is that insulin may partially restore the altered function of the immune system, thereby slowing the autoimmune process. It is of interest that in patients with Type 2 (non-insulin-dependent) diabetes mellitus, immunological abnormalities are not common.
In conclusion, Type 1 diabetes mellitus is characterized by multiple and in some cases transient immunological abnormalities. The idea that a deficiency in insulin or its aberrant regulation may be responsible for certain of the immunological abnormalities associated with Type i diabetes has appeal, but has not been fully proven. What actually triggers the cascade of events leading to pancreatic B-cell destruction, and whether the primary defect resides at the level of the target cells or effector cells, also remains elusive.
